This is potentially relevant to control infection-risk in CLL patients and, thus, future studies should carefully evaluate the effects of CLL therapies, including Btk inhibitors with higher specificity for Btk, on platelet-mediated immune functions. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.